SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
PRINCETON, N.J., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Katie MacFarlane, Chief Commercial Officer, will present at Noble Financial Capital Markets’ Twelfth Annual Equity Conference on Monday, January 18, 2016 at 11:30 AM ET.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability.
Contact Mary Coleman 609-683-1880
